Truist Securities Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $7
Truist Securities Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $7
Truist Securities維持對Sangamo Therapeutics的買入,將目標股價下
Truist Securities analyst Nicole Germino maintains Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and lowers the price target from $8 to $7.
Truist Securities分析師妮可·傑爾米諾維持Sangamo Therapeutics(納斯達克股票代碼:SGMO)的買入,並將目標股價從8美元下調至7美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。